Clinical Trial Update: Short-term Renal Hemodynamic Effects of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating short-term renal hemodynamic effects of tolvaptan in autosomal dominant polycystic kidney disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autosomal Dominant Polycystic Kidney Disease

Drugs mentioned

• tolvaptan (tolvaptan)

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Autosomal Dominant Polycystic Kidney Disease | Phase 2 | Status: COMPLETED | Results posted: 2017-06-28